The 3' end prothrombin gene variants in serbian patients with idiopathic thrombophilia.
Thrombophilia is a multifactorial disorder that arises from the interaction of acquired and genetic risk factors. Despite the significant efforts made to understand the etiology of this disease, there are still a certain number of patients suffering from idiopathic thrombophilia. The aim of this study was to screen the 3' end of the prothrombin (FII) gene, which is susceptible to gain-of-function mutations due to its non canonical architecture, in patients with idiopathic thrombophilia and to determine its eventual role in the pathogenesis of thrombophilia. This study was carried out in 100 patients with idiopathic thrombophilia and 100 healthy controls. DNA variants in the 715 bp long region of the 3' end of the prothrombin gene were identified by sequencing. In our study, we detected two variants: A19911G and C20068T. The frequency of the A19911G gene variant was slightly increased in the group of patients compared to controls, however with no statistically significant difference compared to controls [odds ratio (OR) = 1.06; 95% confidence interval (95% CI) 0.53-2.13]. Heterozygous carriers of the FII C20068T gene variant were four times more frequent in patients (4.0%) than in controls (1.0%), but this difference did not reach statistical significance (OR = 4.12; 95% CI 0.45-37.57). Our findings suggest that variant A19911G is not a significant risk factor, while C20068T may represent a potential risk factor for idiopathic thrombophilia. To confirm our results, further studies should be conducted in a larger cohort of patients.
Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Belgrade, Serbia.
M
M
Aradjanski
Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Belgrade, Serbia.
V
V
Djordjevic
Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Belgrade, Serbia.
I
I
Pruner
Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Belgrade, Serbia.
B
B
Tomic
Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Belgrade, Serbia.
M
M
Gvozdenov
Faculty of Medicine, University of Belgrade, Serbia ; Blood Transfusion Institute of Serbia, Hemostasis Department, Belgrade, Serbia.
M
M
Kovac
Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Belgrade, Serbia.
D
D
Radojkovic
3′ End prothrombin (FII) gene; Gene variants; Thrombophilia